What We're Reading: Page 304
Industry reads hand-picked by our editors
Apr 04, 2017
-
Financial Times
Teva investor warns of rebellion as pressure mounts
-
ProPublica
Tom Price’s $150,000-plus stock windfall
-
MIT Technology Review
U.S. government moves forward with tests of novel Zika vaccine
Apr 03, 2017
-
The Washington Post
The government’s struggle to hold opioid manufacturers accountable
-
Business Insider
A $12 billion startup you've probably never heard wants to cure baldness and smooth out your wrinkles
-
Xconomy
To Infinity and beyond: Julian Adams on missteps and his new job
-
Slate
What exactly is synthetic biology?
Mar 31, 2017
Mar 30, 2017
Mar 29, 2017
-
The American Prospect
The hidden monopolies that raise drug prices
-
Fortune
Trump is slashing FDA rules. Why isn’t big pharma excited?
-
Bloomberg
A new kind of male birth control is coming
-
The Wall Street Journal
FDA nominee plans recusals from decisions on many drug firms
Mar 28, 2017
-
MIT Technology Review
Is this the anti-aging pill we’ve all been waiting for?
-
MarketWatch
Ex-CEO Michael Pearson sues Valeant over unpaid shares
-
The New Yorker
Silicon Valley's quest to live forever
Mar 27, 2017
-
Business Insider
Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll explore
-
PBS
Venezuela’s hospitals face crisis as meds run low
-
The San Diego Union-Tribune
Should some patients be allowed to take drugs not yet cleared by FDA?
-
The Hill
Sanders will 'absolutely' work with Trump to lower prescription drug costs
Previous
